Prognostic significance of molecular classification of breast invasive ductal carcinoma

Muñoz, Mar; Fernández-Aceñero, María Jesús; Martín, Silvia; Schneider, J.

doi:10.1007/s00404-008-0867-1

Cited by 16 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median durations of survival with distant metastasis of HER-2 enriched type and TNBC was only 0.7 and 0.5 years respectively, compared with the luminal type which was from 1.3 to 1.6 years. Munoz et al also concluded that patients with HER-2 enriched tumors or TNBC had a worse outcome with the higher recurrence and mortality rate, shorter relapse free survival and overall survival [25]. Nonetheless, the mechanisms underlying the aggressive behaviors of BC subtypes and prognosis are still unclear.…”

Section: Discussionmentioning

confidence: 96%

“…In our meta-analysis, EZH2 was also found to be associated with the race of BC patients, which implied that EZH2 expression was higher in other racial women than that in white women. Primary molecular subtypes of breast tumors have been defined by clinical markers: Luminal tumors (ER/PR positive and HER-2 negative), HER-2 enriched tumors (ER/PR negative and HER-2 positive) and TNBC (with all markers negative) [25]. Biological behaviors and prognoses of BC with different molecular phenotypes are different [26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis

Wang

Shen

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis

Wang

Shen

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…Other studies have replicated the finding that basal-like breast cancer is more common in young African Americans [3, 9,10] and younger women in Africa [11, 12] compared to European American, European, and Asian women [3-8, 13–21]. Additionally, nearly all studies agree that basal-like and HER2+/ER- negative tumors have poorer prognoses than luminal A, regardless of the source population [3, 4, 6, 7, 10, 15–24].…”

Section: Introductionmentioning

confidence: 83%

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

O’Brien

Cole

Tse

et al. 2010

Clinical Cancer Research

378

296

View full text Add to dashboard Cite

Purpose: Previous research identified differences in breast cancer-specific mortality across 4 intrinsic tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth factor receptor 2 positive/ estrogen receptor negative (HER2Experimental Design: We used immunohistochemical markers to subtype 1,149 invasive breast cancer patients (518 African American, 631 white) in the Carolina Breast Cancer Study, a population-based study of women diagnosed with breast cancer. Vital status was determined through 2006 using the National Death Index, with median follow-up of 9 years.Results: Cancer subtypes luminal A, luminal B, basal-like, and HER2 þ /ER À were distributed as 64%, 11%, 11%, and 5% for whites, and 48%, 8%, 22%, and 7% for African Americans, respectively. Breast cancer mortality was higher for participants with HER2 þ /ER À and basal-like breast cancer compared with luminal A and B. African Americans had higher breast cancer-specific mortality than whites, but the effect of race was statistically significant only among women with luminal A breast cancer. However, when compared with the luminal A subtype within racial categories, mortality for participants with basal-like breast cancer was higher among whites (HR ¼ 2.0, 95% CI: 1.2-3.4) than African Americans (HR ¼ 1.5, 95% CI: 1.0-2.4), with the strongest effect seen in postmenopausal white women (HR ¼ 3.9, 95% CI: 1.5-10.0). Conclusions: Our results confirm the association of basal-like breast cancer with poor prognosis and suggest that basal-like breast cancer is not an inherently more aggressive disease in African American women compared with whites. Additional analyses are needed in populations with known treatment profiles to understand the role of tumor subtypes and race in breast cancer mortality, and in particular our finding that among women with luminal A breast cancer, African Americans have higher mortality than whites. Clin Cancer Res; 16(24); 6100-10. Ó2010 AACR.

show abstract

“…With the advances in molecular biological research, a more in-depth understanding of breast cancer has been developed. Nowadays, breast cancer can be generally classified into luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple negative breast cancer (TNBC) based on the presence or absence of the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 (Ihemelandu et al, 2007;Muñoz et al, 2009;Wiechmann et al, 2009;Park et al, 2012). Breast cancer is a heterogeneous disease consisting of different molecular subtypes with different molecular biological characteristics and clinical behaviors.…”

Section: Introductionmentioning

confidence: 99%

Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. This study aimed to explore new opportunities for developing targeted therapy for triple-negative breast cancer (TNBC) by analyzing the significance and association between p53 and epidermal growth factor receptor (EGFR) expression in different molecular subtypes of breast cancer. The clinical and pathological data of 264 patients with breast cancer receiving surgery in our hospital from January 2012 to August 2013 were retrospectively analyzed. According to the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), Ki-67, CK5/6, p53, and EGFR detected by immunohistochemical methods, breast cancer was divided into four molecular subtypes. Then, the expression of p53 and EGFR as well as their correlation in the different subtypes were determined. Among the four subtypes, luminal B breast cancer was the most common type. TNBC and HER2-enriched breast cancer had larger tumor sizes with higher expression of Ki-67 as compared with the luminal types. TNBC had a lower lymph node metastasis rate but 4283 p53 and EGFR expression in breast cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 4282-4290 (2015) higher CK5/6 and EGFR expression than the other three types. The expression of p53 was higher in luminal B, HER2-enriched, and triplenegative breast cancers, and this was positively correlated with the expression of EGFR in TNBC but not in the other subtypes. p53 and EGFR expression was positively correlated in TNBC, which enables us to explore the molecular biological characteristics of TNBC, so as to provide new ideas for the treatment of TNBC.

show abstract

Prognostic significance of molecular classification of breast invasive ductal carcinoma

Abstract: Molecular classification with immunohistochemistry behaves as a significant prognosticator for breast invasive ductal carcinoma in our series of patients. The worse prognosis observed for Her2 expressing lesions may have changed after trastuzumab use.

Cited by 16 publications

References 13 publications

Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis

Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification

Contact Info

Product

Resources

About